OverviewSuggest Edit

Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer. The company works on programs in severe genetic diseases that include betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia); LentiGlobin gene therapy for sickle cell disease, or SCD; and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy, or CALD). Its programs in oncology are focused on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.

TypePublic
Founded1992
HQCambridge, MA, US
Websitebluebirdbio.com
Employee Ratings3.4
Overall CultureC+

Latest Updates

Employees (est.) (Jan 2021)1,213(+4%)
Job Openings114
Revenue (FY, 2020)$250.7 M(+462%)
Share Price (Sept 2021)$17.6(-3%)
Cybersecurity ratingBMore

Key People/Management at Bluebird Bio

Nick Leschly

Nick Leschly

CEO, Director
Jason F. Cole

Jason F. Cole

Chief Operating & Legal Officer
Chip Baird

Chip Baird

Chief Financial Officer
Elizabeth Pingpank

Elizabeth Pingpank

Director, Investor Relations
Anne-Virginie Eggimann

Anne-Virginie Eggimann

Chief Regulatory Officer
Doug Danison

Doug Danison

Head of Europe
Show more

Bluebird Bio Office Locations

Bluebird Bio has offices in Cambridge, Durham, Seattle, Paris and in 6 other locations
Cambridge, MA, US (HQ)
60 Binney St
Durham, NC, US
1733 TW Alexander Dr
Seattle, WA, US
188 E Blaine St #300
Paris, FR
75 Boulevard Haussmann
München, DE
Josephspitalstraße 15
Athens, GR
166A, Kifissias Avenue & 2 Sofokleous Str. GR-151 26 Maroussi
Show all (10)

Bluebird Bio Financials and Metrics

Bluebird Bio Revenue

Embed Graph
View revenue for all periods
Bluebird Bio's revenue was reported to be $250.73 m in FY, 2020 which is a 461.3% increase from the previous period.
USD

Revenue (Q1, 2021)

12.8m

Gross profit (Q1, 2021)

10.5m

Gross profit margin (Q1, 2021), %

82.2%

Net income (Q1, 2021)

(205.8m)

EBIT (Q1, 2021)

(231.2m)

Market capitalization (14-Sept-2021)

1.2b

Closing stock price (14-Sept-2021)

17.6

Cash (31-Mar-2021)

439.7m

EV

950.4m
Bluebird Bio's current market capitalization is $1.2 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

54.6m44.7m250.7m

Revenue growth, %

(18%)461%

Cost of goods sold

885.0k3.0m5.4m

Gross profit

53.7m41.7m245.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

12.5m13.3m8.9m21.9m198.9m19.3m12.8m

Cost of goods sold

430.0k613.0k862.0k1.0m1.6m1.3m2.3m

Gross profit

12.0m12.7m8.0m20.8m197.3m18.0m10.5m

Gross profit Margin, %

97%95%90%95%99%93%82%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

402.6m327.2m317.7m

Accounts Receivable

13.9m12.8m26.8m

Prepaid Expenses

19.8m32.9m37.5m

Current Assets

1.4b1.2b1.2b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

221.7m281.0m300.4m346.6m1.2b324.2m439.7m

Accounts Receivable

19.4m21.5m13.1m16.6m24.7m25.5m24.8m

Prepaid Expenses

23.8m25.4m26.9m40.2m39.4m35.4m42.3m

Inventories

18.1m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(555.6m)(789.6m)(618.7m)

Depreciation and Amortization

17.2m17.4m19.4m

Accounts Payable

3.6m23.6m(20.1m)

Cash From Operating Activities

(413.4m)(564.4m)(470.4m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(164.4m)(360.2m)(566.3m)(202.6m)(224.1m)(418.8m)(205.8m)

Depreciation and Amortization

3.8m7.8m12.4m4.9m9.4m14.4m5.4m

Inventories

(7.1m)

Accounts Payable

10.6m6.7m23.3m(9.5m)(14.0m)(15.4m)67.0k
USDFY, 2018

EV/EBIT

-9 x

EV/CFO

-12.5 x

Revenue/Employee

96.8k

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x

P/E Ratio

(9.3)
Show all financial metrics

Bluebird Bio Operating Metrics

FY, 2018FY, 2019FY, 2020

Patents and Patent Applications

9361.17 k1.22 k
Show all operating metrics

Bluebird Bio Acquisitions / Subsidiaries

Company NameDateDeal Size
PregenenJuly 01, 2014$139.9 m
bluebird bio Australia Pty Ltd
bluebird bio (Bermuda) Ltd
bluebird bio France, SARL
bluebird bio (FR) SAS
bluebird bio (Germany) GmbH
Bluebird Bio Greece Single Member, L.L.C.
bluebird bio, Inc.
bluebird bio (Italy) Srl
bluebird bio (Netherlands) B.V.
Show more

Bluebird Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Bluebird Bio Online and Social Media Presence

Embed Graph

Bluebird Bio Company Culture

  • Overall Culture

    C+

    73/100

  • CEO Rating

    B

    77/100

  • Compensation

    D

    55/100

Learn more on Comparably

Bluebird Bio News and Updates

bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU

bluebird bio announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favor…

bluebird bio Responds to Marketing Campaign Lawsuit with Countersuit

In a countersuit filed July 2, Cambridge, Mass.-based bluebird bio is hitting back at Roche-owned Spark Therapeutics over the use of the word “spark” in promotional campaigns involving the company’s “Be the Spark” campaign against sickle cell disease

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies

bluebird bio announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-20…

bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of common stock and 25,000 restricted stock units (“RSUs”) to its Chief Commercial Officer Tom Klima with a grant date of June 1…

bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)

bluebird bio announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for SKYSONA™ (elivaldogene autotemcel, Lenti-D™), a one-time gene therapy for the treatment of early cerebral a…

bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress

bluebird bio announced that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM) will be presented during EHA2021 Virtual, the 26th Annual Congress of the Euro…
Show more

Bluebird Bio Frequently Asked Questions

  • When was Bluebird Bio founded?

    Bluebird Bio was founded in 1992.

  • Who are Bluebird Bio key executives?

    Bluebird Bio's key executives are Nick Leschly, Jason F. Cole and Chip Baird.

  • How many employees does Bluebird Bio have?

    Bluebird Bio has 1,213 employees.

  • What is Bluebird Bio revenue?

    Latest Bluebird Bio annual revenue is $250.7 m.

  • What is Bluebird Bio revenue per employee?

    Latest Bluebird Bio revenue per employee is $206.7 k.

  • Who are Bluebird Bio competitors?

    Competitors of Bluebird Bio include Tanvex Biopharma, H3 Biomedicine and G1 Therapeutics.

  • Where is Bluebird Bio headquarters?

    Bluebird Bio headquarters is located at 60 Binney St, Cambridge.

  • Where are Bluebird Bio offices?

    Bluebird Bio has offices in Cambridge, Durham, Seattle, Paris and in 6 other locations.

  • How many offices does Bluebird Bio have?

    Bluebird Bio has 10 offices.